Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DE GERMAY, Sibylle | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PAMBRUN, Elodie | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PARIENTE, Antoine
IDREF: 13395711X | |
| dc.contributor.author | GRENET, Guillaume | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BEZIN, Julien | |
| dc.contributor.author | FAILLIE, Jean Luc | |
| dc.date.accessioned | 2024-02-21T15:39:43Z | |
| dc.date.available | 2024-02-21T15:39:43Z | |
| dc.date.issued | 2024-01-30 | |
| dc.identifier.issn | 1463-1326 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/188300 | |
| dc.description.abstractEn | AIM: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have been commercialized in France for type 2 diabetes since April 2020 and later for heart and renal diseases. Given the recent developments in treating diabetes and the widening of SGLT-2i indications, we aimed to study changes in the use of glucose-lowering drugs in France and to characterize SGLT-2i new users. METHODS: We performed a nationwide utilization study using the French health insurance database. Trends in incidence and prevalence of glucose-lowering drug use were assessed by a repeated cross-sectional study in 2019 and 2021. A cohort study of incident SGLT-2i users was then conducted to describe patient characteristics and the strategy for treating diabetes. RESULTS: The prevalence of SGLT-2i use gradually reached 0.1% in the third quarter of 2021 and increased more significantly to 0.2% thereafter. SGLT-2i became the second most prescribed glucose-lowering drug class after metformin at the end of 2021 (0.1%). Among the cohort of 125 387 SGLT-2i new users (mean age 65.0 years; 60.1% of men), 87.6% presented a diabetic comorbidity. The patient profile changed over the study period with an increasing proportion of patients with cardiovascular (28.7% in 2020 vs. 40.2% in 2021) or renal (7.7% in 2020 vs. 11.8% in 2021) comorbidities at initiation. The main combinations used at SGLT-2i initiation were metformin (12.5%) and metformin plus dipeptidyl peptidase-4 inhibitors (8.1%). One-year probability of SGLT-2i persistence was estimated to be 55%. CONCLUSION: The expansion of indications for SGLT-2i and the broadening of the target population make it essential to assess the reasons for discontinuation and review their safety profile. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | type 2 diabetes | |
| dc.subject.en | sodium-glucose cotransporter-2 inhibitor | |
| dc.subject.en | pharmacoepidemiology | |
| dc.subject.en | antidiabetic drug | |
| dc.title.en | Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database | |
| dc.title.alternative | Diabetes Obes Metab | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/dom.15472 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38288619 | en_US |
| bordeaux.journal | Diabetes, Obesity and Metabolism | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Agence Nationale de Sécurité du Médicament et des Produits de Santé | en_US |
| hal.identifier | hal-04471475 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-02-21T15:39:46Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes,%20Obesity%20and%20Metabolism&rft.date=2024-01-30&rft.eissn=1463-1326&rft.issn=1463-1326&rft.au=DE%20GERMAY,%20Sibylle&PAMBRUN,%20Elodie&PARIENTE,%20Antoine&GRENET,%20Guillaume&BEZIN,%20Julien&rft.genre=article |
